Probiotics: Preventing Antibiotic-Associated Diarrhea

Journal for Specialists in Pediatric Nursing (Impact Factor: 0.92). 04/2010; 15(2):160-2. DOI: 10.1111/j.1744-6155.2010.00231.x
Source: PubMed


Probiotics are live microorganisms that offer a health benefit to the host. Found typically in dietary supplements, probiotics can be safely used in the treatment of acute diarrheal disease, inflammatory bowel disease, and antibiotic-associated diarrhea. They can be found in milks, yogurt, powders, and pills.
Research has shown that several strains of probiotics are helpful in the prevention and treatment of antibiotic-associated diarrhea. The most commonly studied probiotics are Lactobacillus GG and Saccharomyces boulardii.
By understanding the uses, dosages, and safety of common probiotics, nurses can help educate patients and their families on the benefits of probiotics.

1 Follower
13 Reads

  • Expert Review of Anti-infective Therapy 04/2012; 10(4):407-9. DOI:10.1586/eri.12.24 · 3.46 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: We investigated the efficacy of treatment with multi-species probiotics on IBS symptoms and the alterations of gut microbiota in patients who have taken probiotics. This randomized, double-blind, placebo-controlled trial involved 49 IBS patients (probiotics: 25, placebo: 24) diagnosed according to the Rome III criteria. Patients were randomly assigned to two groups: either to receive multi-species probiotics (a mixture of Bifidobacterium longum, Bifidobacterium bifidum, Bifidobacterium lactis, Lactobacillus acidophilus, Lactobacillus rhamnosus, and Streptococcus thermophilus) twice a day for four weeks, or to receive a placebo twice a day for four weeks. The primary efficacy endpoint was the proportion of participants whose IBS symptoms were substantially relieved at week 4. Secondary endpoints were the intensity of abdominal pain/discomfort, bloating, stool frequency/consistency, alterations in fecal microflora over the four weeks. Fecal microflora were analyzed in 34 patients (probiotics: 17, placebo: 17) by quantitative real-time PCR assays. The proportion of patients whose IBS symptoms were substantially relieved at week 4 was significantly higher in the probiotics group than in the placebo group: 68.0% (17/25) vs. 37.5% (9/24) (p<0.05). Secondary endpoints such as improvement in abdominal pain/discomfort and bloating occurred in the probiotics group but not in the placebo group. Fecal analysis revealed that B. lactis, L. rhamnosus and S. thermophilus had increased significantly in the probiotics group after four weeks, and that B. lactis had increased in the placebo group. Multi-species probiotics are effective in IBS patients, and induced the alterations in the composition of intestinal microbiota.
    Journal of Gastroenterology and Hepatology 07/2013; 29(1). DOI:10.1111/jgh.12322 · 3.50 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: This study aimed to isolate Lactobacillus species from yoghurt and to evaluate its antimicrobial activity against enterohemorrhagic Escherichia coli O157:H7. After incubation of different yoghurt samples in MRS (de Man, Rogosa and Sharpe) agar at 37C under anaerobic conditions, four Lactobacillus species, L. casei, L. acidophilus, L. helveticus and L. delbrueckii ssp. bulgaricus were identified. Standard growth curves of E. coli O157:H7 in proximity with lactobacilli test strains were obtained. The antibacterial effects of lactobacilli cell debris and culture supernatant against E. coli O157:H7 were determined. The results showed that the antibacterial effects of culture supernatant were stable at different temperature conditions (56–100C) for 30 and 60 min; also, it was stable at pH 3–10. With regard to the antibacterial effect of the lactobacilli strains in this study, they may help in the treatment of E. coli O157:H7-associated diseases and can be applied as a biological preservative in the food industry.Practical ApplicationsIn recent years, foodborne diseases become a health problem in most of the population. One of the most important etiologic agents of such diseases is Escherichia coli O157:H7, which can be transmitted through eating undercooked infected meat and leads to hemorrhagic diarrhea and kidney failure. There is increasing evidence that lactobacilli bacteria produce potential agents (H2O2, small organic compounds, lactic acid, etc.) that can inhibit growths of some invasive foodborne bacteria, such as enterohemorrhagic E. coli. The results of this study also confirmed these reports and showed that the use of lactobacilli bacteria is a promising way to prevent the infection of E. coli O157:H7; also, they can be used as a biological preservative in the food industry.
    04/2014; 34(2). DOI:10.1111/jfs.12108
Show more


13 Reads
Available from